Navigation Links
Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
Date:12/20/2007

New Board Member Brings Life Sciences Tools Experience to the Leader in

Cellular Bioenergetic Profiling

N. BILLERICA, Mass., Aug. 10 /PRNewswire/ -- Seahorse Bioscience, the leading provider of tools for real-time measurement of cellular bioenergetics in microplates, announced today that former Molecular Devices executive Joseph Keegan has been appointed to the company's Board of Directors. In this position, Keegan will apply his successful business experience in the life sciences industry to accelerate the growth of Seahorse Bioscience's novel technology for profiling cell metabolism.

"As the company moves into its next phase of growth, it will require a strong understanding of this market," said Jay Teich, Seahorse Bioscience's CEO. "Joe's tremendous success in building Molecular Devices, combined with his extensive labware experience makes him an ideal addition to our Board."

Keegan brings more than 25 years of experience managing life science tools businesses. As CEO of Molecular Devices, he developed a strategy combining internal growth with acquisitions to build the dominant supplier of detection solutions for drug discovery, clinical and research applications. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture. Prior to Becton Dickinson, Keegan was Vice President of Microscopy and Scientific Instruments Division of Leica, Inc.

"Seahorse has developed a 'stethoscope for living cells.' The ability to measure cell metabolism in a truly non-invasive way has very broad applications," said Keegan. "Drawing on my experience with both instrument and labware businesses, I look forward to helping Seahorse grow a successful business in a field that I understand very well."

About Seahorse Bioscience

Seahorse Bioscience is changing cancer, obesity and diabetes drug discovery programs the world over. Seahorse headquarters are located in North Billerica, Massachusetts. For more information, please visit http://www.seahorsebio.com.

Media Contact:

Cheryle Cushion

Seahorse Bioscience

(978) 671-1697

ccushion@seahorsebio.com


'/>"/>
SOURCE Seahorse Bioscience
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):